← Leaderboards
Dennis L Wright
University Of Connecticut Sch Of Med/Dnt
$12,674,619
Attributed
$16,759,191
Total exposure
20
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2006–24$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$16,759,191 · 20
By mechanism
R01$9,322,791 · 3
R42$2,516,144 · 2
R41$2,177,020 · 6
R21$2,129,455 · 5
R56$605,273 · 1
P41$8,508 · 3
Top collaborators
- Sandra K Weller9 shared
- Amy C. Anderson5 shared
- Akiko Nishiyama2 shared
Most similar at University Of Connecticut Sch Of Med/Dnt
Same institution · by research overlap
- Sandra K Weller$19,615,897
Others in their field
Top investigators on “Enzymes”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$143,577,666
- Randall J Bateman · Washington University$83,824,814
- Stuart L Schreiber · Harvard University (Medical School)$49,424,554
- Jay D Keasling · University Of California-Berkeley$47,558,861
- David Heimbrook · Leidos Biomedical Research, Inc.$47,513,682
- Susan Abushakra · Alzheon, Inc.$47,265,244
Research focus
EnzymesLeadInfectionIn VivoOrganismProteinsStructureEvaluationResistanceBaseDesignCellsIn VitroPathogenInhibitor/AntagonistPropertyAnalogBiochemicalFolic Acid AntagonistsDihydrofolate ReductaseGenerationsToxic EffectDrug KineticsComplex
Grant awards (40)
Genetics of HSV DNA Replication$789,284
R01 · FY2024 · AI
Therapeutic Agents Targeting Cryptococcal Infections$297,725
R41 · FY2024 · AI · contact PI
Genetics of HSV DNA Replication$790,597
R01 · FY2023 · AI
Exploring herpesvirus exonucleases as potential antiviral targets$605,273
R56 · FY2023 · AI
Therapeutic Agents Targeting Cryptococcal Infections$300,000
R41 · FY2023 · AI · contact PI
New Agents for the Treatment on Mycobacteria Avium Infections$300,000
R41 · FY2023 · AI · contact PI
Genetics of HSV DNA Replication$791,737
R01 · FY2022 · AI
New Agents for the Treatment on Mycobacteria Avium Infections$300,000
R41 · FY2022 · AI · contact PI
Genetics of HSV DNA Replication$792,279
R01 · FY2021 · AI
Exploring the Coronavirus Exoribonuclease as an Antiviral Target$463,700
R21 · FY2021 · AI
Genetics of HSV DNA Replication$824,140
R01 · FY2020 · AI
Antimetabolites for Acute Myeloid Leukemias$300,000
R41 · FY2020 · CA · contact PI
Development of Broad Spectrum Antifungal Agents$300,000
R41 · FY2020 · AI · contact PI
Targeting viral alkaline nucleases for the development of broad spectrum anti-herpesvirus therapeutics$203,500
R21 · FY2020 · AI
Targeting viral alkaline nucleases for the development of broad spectrum anti-herpesvirus therapeutics$260,500
R21 · FY2019 · AI
Targeting Glycolytic Enzymes as an Antibacterial Strategy$199,375
R21 · FY2019 · AI · contact PI
Propargyl-linked Antifolates Targeting Klebsiella pneumoniae$678,458
R01 · FY2018 · AI · contact PI
Targeting Glycolytic Enzymes as an Antibacterial Strategy$239,250
R21 · FY2018 · AI · contact PI
Propargyl-linked Antifolates Targeting Klebsiella pneumoniae$696,770
R01 · FY2017 · AI · contact PI
Antimetabolites Effective against Resistant Gram-positive Bacteria$543,157
R01 · FY2017 · AI · contact PI
Propargyl-linked Antifolates Targeting Klebsiella pneumoniae$627,479
R01 · FY2016 · AI · contact PI
Antimetabolites Effective against Resistant Gram-positive Bacteria$543,157
R01 · FY2016 · AI · contact PI
Propargyl-linked Antifolates Targeting Klebsiella pneumoniae$35,041
R01 · FY2016 · AI
Propargyl-linked Antifolates Targeting Klebsiella pneumoniae$547,689
R01 · FY2015 · AI
Antimetabolites Effective against Resistant Gram-positive Bacteria$543,157
R01 · FY2015 · AI · contact PI
Propargyl-linked Antifolates Targeting Klebsiella pneumoniae$562,189
R01 · FY2014 · AI
Antimetabolites Effective against Resistant Gram-positive Bacteria$557,657
R01 · FY2014 · AI · contact PI
HDAC Inhibitors Inspired by Natural Products$163,074
R21 · FY2012 · CA · contact PI
Potent Antifolates as New Therapeutics for MRSA$763,661
R42 · FY2011 · AI · contact PI
Regulation of glial lineage by Olig2$219,968
R21 · FY2011 · NS
HDAC Inhibitors Inspired by Natural Products$197,655
R21 · FY2011 · CA · contact PI
Potent Antifolates as New Therapeutics for MRSA$754,203
R42 · FY2010 · AI · contact PI
Regulation of glial lineage by Olig2$182,433
R21 · FY2010 · NS
STRATEGIC USE OF FURAN IN THE SYNTHESIS OF MOLECULES OF BIOLOGICAL IMPORTANCE$425
P41 · FY2008 · RR · contact PI
Natural feedstocks for diversity-oriented synthesis$481,066
R42 · FY2007 · GM · contact PI
STRATEGIC USE OF FURAN IN THE SYNTHESIS OF MOLECULES OF BIOLOGICAL IMPORTANCE$6,778
P41 · FY2007 · RR · contact PI
Natural feedstocks for diversity-oriented synthesis$517,214
R42 · FY2006 · GM · contact PI
Potent and selective DHFR inhibitors for treating Cryptosporidiosis$279,271
R41 · FY2006 · AI · contact PI
STRATEGIC USE OF FURAN IN THE SYNTHESIS OF MOLECULES OF BIOLOGICAL IMPORTANCE$1,305
P41 · FY2006 · RR · contact PI
Natural feedstocks for diversity oriented synthesis$100,024
R41 · FY2004 · GM